Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male Mecp2 mutant mice by E. Zamberletti et al.
1 
 
Cannabidivarin completely rescues cognitive deficits and delays 1 
neurological and motor defects in male Mecp2 mutant mice 2 
 3 
Zamberletti E.1, Gabaglio M.1, Piscitelli F.2, Brodie J.S.3, Woolley-Roberts M.3, 4 
Barbiero I.1, Tramarin M.1, Binelli G.1, Landsberger N.4, Kilstrup-Nielsen C.1, 5 
Rubino T.1, Di Marzo V.2, Parolaro D.1,5 6 
 7 
1Dept. of Biotechnology and Life Sciences (DBSV), University of Insubria, 8 
Varese, Italy; 2Endocannabinoid Research Group, Institute of Biomolecular 9 
Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, Naples, Italy; 3GW 10 
Research Ltd, Cambridge (UK); 4Dept. of Medical Biotechnology and 11 
Translational Medicine, University of Milan, Italy; 5Zardi Gori Foundation, Milan 12 
(Italy). 13 
 14 
Corresponding author: 15 
Daniela Parolaro 16 
DBSV, University of Insubria and Zardi Gori Foundation 17 
Tel. +39 0331339417 18 
Fax. +39 0331339459 19 
Email daniela.parolaro@uninsubria.it 20 
2 
 
Abstract 1 
Background: Recent evidence suggests that 2-week treatment with the non-2 
psychotomimetic cannabinoid cannabidivarin (CBDV) could be beneficial towards 3 
neurological and social deficits in early symptomatic Mecp2 mutant mice, a model 4 
of Rett syndrome (RTT). 5 
Aim: To provide further insights into the efficacy of CBDV in Mecp2-null mice we 6 
used a lifelong treatment schedule (from 4 to 9 weeks of age) and evaluated its 7 
effect on recognition memory and neurological defects in both early and 8 
advanced stages of the phenotype progression. 9 
Methods: CBDV 0.2, 2, 20, 200 mg/kg/day was administered to Mecp2-null mice 10 
from 4 to 9 weeks of age. Cognitive and neurological defects were monitored 11 
during the whole treatment schedule. Biochemical analyses were carried out in 12 
brain lysates from 9-week-old wildtype and knockout mice to evaluate brain-13 
derived neurotrophic factor (BDNF) and insulin-like growth factor-1 (IGF-1) levels 14 
as well as components of the endocannabinoid system. 15 
Results: CBDV rescues recognition memory deficits in Mecp2 mutant mice and 16 
delays the appearance of neurological defects. At the biochemical level, it 17 
normalizes BDNF/IGF1 levels and the defective PI3K/AKT/mTOR pathway in 18 
Mecp2 mutant mice at an advanced stage of the disease. Mecp2 deletion 19 
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upregulates CB1 and CB2 receptor levels in the brain and these changes are 1 
restored after CBDV treatment. 2 
Conclusions: CBDV administration exerts an enduring rescue of memory 3 
deficits in Mecp2 mutant mice, an effect that is associated with the normalization 4 
of BDNF, IGF-1 and rpS6 phosphorylation levels as well as CB1 and CB2 5 
receptor expression. CBDV delays neurological defects but this effect is only 6 
transient. 7 
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1. Introduction 1 
Rett syndrome (RTT) is an X-linked dominant neurodevelopmental disorder with 2 
a prevalence rate of 1 in 10,000 females. RTT patients have apparently normal 3 
perinatal development until about 6–18 months of age, after which they undergo 4 
a period of rapid regression, characterized by the appearance of autistic features, 5 
cognitive regression, stereotypic hand movements and loss of language. RTT 6 
girls also have seizures during childhood, breathing arrhythmias, develop 7 
scoliosis and lose mobility between ages 1 and 4 years (Chahrour and Zoghbi, 8 
2007; Hagberg, 2002; Neul et al., 2014). 9 
Mutations affecting the methyl-CpG-binding protein 2 (MeCP2) represent the 10 
almost exclusive cause of the disorder (Amir et al., 1999). Given the location of 11 
the MECP2 gene on the X chromosome, males with MECP2 mutations are more 12 
severely affected and rarely survive infancy while females, owing to X 13 
chromosome inactivation, are mosaics with cells that express either the wild-type 14 
(WT) or mutant version of MeCP2 (Chahrour and Zoghbi, 2007). 15 
Mecp2 deficiency in mice closely mimics the clinical features of the human 16 
disorder, including motor and neurological defects and breathing abnormalities 17 
(Ricceri et al., 2008), possibly reflecting the high conservation of the MeCP2 18 
amino acid sequence and the parallel dynamics of MeCP2 expression during 19 
brain development in the two species. Thus, despite differences in brain structure 20 
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and developmental timing between humans and mice, the molecular 1 
consequences of the MeCP2 mutation appear to be similar in the two species, 2 
and mouse models represent an essential tool for testing potential treatment 3 
strategies for RTT. 4 
Converging evidence points to a role for endocannabinoid signaling dysregulation 5 
in the pathophysiology of neurodevelopmental conditions including social 6 
dysfunction and autism spectrum disorder (ASD) (Karhson et al., 2016; Wei et 7 
al., 2017; Zamberletti et al., 2017). Remarkably, improvement in social 8 
functioning and anxiety-like behavior was consistently reported following 9 
pharmacological modulation of different components of the endocannabinoid 10 
system in genetic and environmental models of autism (Busquets-Garcia et al., 11 
2013; Gomis-González et al., 2016; Hosie et al., 2018; Kerr et al., 2016; Servadio 12 
et al., 2016; Jung et al., 2012; Wei et al., 2016). In line with animal data, recent 13 
human findings support a link between altered endocannabinoid activity and 14 
autism (Karhson et al., 2018) possibly suggesting that compounds acting on the 15 
endocannabinoid system could be beneficial in alleviating ASD symptoms. 16 
Phytocannabinoids are terpenophenolic constituents of the cannabis sativa plant 17 
that, in addition to their effects on the endocannabinoid system, exhibit a range 18 
of neuromodulatory, neuroprotective, anti-oxidant and anti-inflammatory 19 
properties, including effects on biochemical pathways that could contribute to 20 
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achieve an overall therapeutic effect in major neurological disorders (Campos et 1 
al., 2016; Fernandez-Ruiz et al., 2013; Ligresti et al., 2016; Nagarkatti et al., 2 
2009). Delta-9-tetrahydrocannabinol (THC) is the major psychotomimetic 3 
component of cannabis whose euphoric effects are mediated by the activation of 4 
CB1 receptors in the central nervous system; however, this mechanism is  5 
responsible for many untoward adverse effects, whose risk is greater with early 6 
use and high doses (Volkow et al., 2014), thus discouraging its use among 7 
children and high-risk groups. Unlike THC, other phytocannabinoids with weak or 8 
no psychotropic activity seem to hold great yet unexplored promise as therapeutic 9 
agents for complex and multifaceted neurodevelopmental diseases. Cannabidiol 10 
(CBD) and cannabidivarin (CBDV) are both effective in ameliorating epilepsy 11 
(Brodie and Ben-Menachem, 2017) and motor dysfunctions (Iannotti et al., 2018), 12 
two conditions frequently observed also in RTT patients (Steffenburg et al., 2001; 13 
Huppke et al., 2007), supporting their potential as treatment options for RTT. 14 
Accordingly, a recent paper showed that a 2-week long treatment schedule with 15 
CBDV could be beneficial towards neurological and social deficits in early 16 
symptomatic Mecp2 mutant mice, a model for RTT, possibly via its action at 17 
GPR55 receptors (Vigli et al., 2018). Both CBD and CBDV activate and 18 
desensitize TRPV1 cation channels and modulate anandamide uptake. 19 
Additionally, CBDV also modulates the levels of the endocannabinoid 2-AG (De 20 
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Petrocellis et al., 2011; 2012), which is crucially involved in synaptic plasticity and 1 
cognitive processes (Zhang et al., 2014). 2 
To gain more insight into the possible efficacy of CBDV in the context of RTT, in 3 
this study we provided additional pieces of data by testing the effect of similar 4 
doses of CBDV in another animal model of RTT, namely Mecp2-null mice, using 5 
a lifelong treatment schedule (from 4 to 9 weeks of age). CBDV effects on 6 
recognition memory and neurological deficits were monitored throughout the 7 
entire animals’ lifespan. At an advanced stage of the phenotype progression (9-8 
week old mice), biochemical analysis were performed to assess whether CBDV 9 
could modulate neurochemical abnormalities that are found in the brain of Mecp2-10 
null mice. In particular, we investigated CBDV’s effect on brain-derived 11 
neurotrophic factor (BDNF), insulin-like growth factor-1 (IGF-1) and their common 12 
downstream PI3K/Akt/mTOR signaling pathway whose reduced levels have been 13 
implicated in the disease progression (Castro et al., 2014; Li and Pozzo-Miller, 14 
2014; Ricciardi et al., 2011) and we analyzed nuclear volumes in the layer V of 15 
the medial prefrontal cortex (mPFC) and CA1 region of the hippocampus, whose 16 
reduction represents a consistent feature of Mecp2 deficiency at the cellular level 17 
(Gadalla et al., 2013; Giacometti et al., 2007). Finally, given that altered 18 
endocannabinoid activity contributes to the pathogenesis of several psychiatric 19 
conditions including anxiety-related disorders, intellectual disabilities, major 20 
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motor disorders, seizures and autism (Campolongo and Trezza, 2012; 1 
Fernández-Ruiz and Gonzáles, 2005; Katona, 2015; Zamberletti et al., 2017), we 2 
investigated the status of components of the endocannabinoid system, in terms 3 
of endocannabinoid levels, enzymatic machinery and CB1, CB2 receptors. 4 
2. Experimental procedures 5 
2.1.1 Animals 6 
We used the CD1 Mecp2-null mouse strain described in Cobolli Gigli et al. (2016). 7 
All experimental procedures were carried out in male Mecp2 WT and KO mice, 8 
housed in groups of 4-5 in clear plastic cages (33.1x15.9x13.2 cm) on a 12 h 9 
light-dark cycle (lights on 8:00 AM) and in a temperature- (22 ± 2°C) and humidity-10 
controlled environment (50 ± 10%) with a plastic tube for environmental 11 
enrichment and free access to food and water. Experimental procedures were 12 
performed in accordance with the guidelines released by the Italian Ministry of 13 
Health (D.L. 2014/26) and the European Community directives regulating animal 14 
research (2010/63/EU). Protocols were approved by the Italian Minister for 15 
Scientific Research and all efforts were made to minimize the number of animals 16 
used and their suffering. 17 
2.1.2 Breeding procedure and genotyping 18 
Wild-type CD1 males and Mecp2+/- heterozygous CD1 females aged between 2 19 
and 4 months were mated for four days. Dams gave birth and raised their litters 20 
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until weaning. Litters were not culled and no selection other than genotype was 1 
made. Mouse genotypes were determined through PCR on genomic DNA 2 
purified from tail biopsy. Biopsies were obtained within the third and fourth week 3 
of life. Forward PCR primer sequences: 5’-CCATGCGATAGGCTTGATGA for the 4 
identification of the null allele, 5’-GACCCCTTGGGACTGAAGTT  for the wt allele. 5 
Common reverse primer sequence: 5’-CCACCCTCCAGTTTGGTTTA . The 6 
obtained PCR products were: a single band of 450 base pairs (bp) for the Mecp2-7 
null mice; a single band of 400 bp for the wt animals and the two bands for 8 
heterozygous females. 9 
2.2 Treatment 10 
A total of 112 littermate male mice from 4 different cohorts were used in the study. 11 
Based on the available litters at weaning, animals were randomly divided into 10 12 
treatment groups: 22 for WT-vehicle, 10 for WT-CBDV 0.2 mg/kg, 13 for WT-13 
CBDV 2 mg/kg, 12 for WT-CBDV 20 mg/kg, 3 for WT-CBDV 200 mg/kg, 11 for 14 
KO-vehicle, 6 for KO-CBDV 0.2 mg/kg, 13 for KO-CBDV 2 mg/kg, 14 for KO-15 
CBDV 20 mg/kg and 8 for KO-CBDV 200 mg/kg. 16 
Purified CBDV (96.4%; CBD 3.6%) was provided by GW Research (Cambridge, 17 
UK), stored at -20°C and freshly prepared daily by dissolution in ethanol, kolliphor 18 
EL and saline (2:1:17). The treatments started at PND 28 (week 4) and lasted 19 
until PND 67 (week 9). Mice received a daily intraperitoneal injection of CBDV (or 20 
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vehicle) at the doses of 0.2, 2, 20 or 200 mg/kg between 9:00 am and 11:00 am 1 
based on previous pharmacokinetic (Deiana et al., 2012) and in vivo (Vigli et al., 2 
2018) studies. 3 
2.3 Behavioral studies 4 
Behavioral testing was carried out by two observers blind to the treatment 5 
conditions. The timeline of the experiments is reported in supplementary figure 6 
S1. 7 
2.3.1 Score test 8 
Neurological defects in Mecp2-null mice were evaluated using observational 9 
scoring for hindlimb clasping, gait, breathing, tremor, mobility and general 10 
condition. Starting from PND 28, Mecp2 WT and KO mice were scored every 11 
other day to evaluate the effect of CBDV treatment on motor symptoms, 12 
neurological signs and general condition. Score data were expressed as the 13 
weekly average of four-day observations in each corresponding week. Each of 14 
the six symptoms was scored from 0 to 2 (0 corresponds to the symptom being 15 
absent or the same as in the WT animal; 1 when the symptom was present; 2 16 
when the symptom was severe) as previously described (Guy et al., 2007; 17 
Szczesna et al., 2014; see Supplementary Methods for a detailed description). 18 
Whenever a mouse scored 2 out of 2 in the three criteria tremor, breathing, 19 
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general condition, or lost 20% of its body weight during the experiment, it was 1 
killed by cervical dislocation. 2 
2.3.2 Novel object recognition (NOR) test 3 
The test was performed on PND 41, 56 and 66. The experimental apparatus used 4 
for the NOR test was an open-field box (43x43x32 cm) made of Plexiglas, placed 5 
in a dimly illuminated room. Animals performed each test individually as in 6 
Zamberletti et al. (2015). Each animal was placed in the arena and allowed to 7 
explore two identical previously unseen objects for 10 minutes (familiarization 8 
phase). The test phase was performed after an inter-trial interval of 30 minutes. 9 
During the test phase, the time spent exploring the familiar object (Ef) and the 10 
new object (En) was recorded separately by two observers blind to the groups 11 
and the discrimination index was calculated as follows: (En-Ef)/(En+Ef) x 100. 12 
Objects were changed in subsequent testing sessions of the NOR test. 13 
2.4 Biochemical studies 14 
2.4.1 Western blot 15 
Mice having all the same age (9 weeks old) were sacrificed by cervical dislocation 16 
24 hours after the last CBDV (or vehicle) injection. The brains were quickly 17 
removed, frozen in liquid nitrogen and stored at -80°C. 18 
50 µg of total protein lysates from hemisected brains were run on a SDS-19 
polyacrylamide gel. The proteins were transferred to polyvinylidene difluoride 20 
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(PVDF) membranes and blocked for 2 hours before incubation overnight at 4°C 1 
with specific primary antibodies (listed in supplementary Table S1). Bound 2 
antibodies were detected with horseradish peroxidase (HRP) conjugated 3 
secondary anti-rabbit or anti-goat antibody (1:2000-1:5000; Chemicon 4 
International, Temecula, CA). The blots were normalized against mouse anti-β-5 
actin monoclonal antibody (1:10000; Sigma Aldrich, Italy), rabbit polyclonal anti-6 
totalAKT (1:1000; Abcam, Cambridge, UK), rabbit polyclonal anti-totalS6 (1:1000; 7 
Cell Signaling, Danvers, MA) or rabbit polyclonal anti-totalERK1/2 (1:1000; Cell 8 
Signaling, Danvers, MA). Bound antibodies were visualized using Clarity Western 9 
ECL Substrate (Bio-Rad Laboratories, Hercules, CA, USA) and bands were 10 
detected with a GBOX XT camera (Syngene, Cambridge, UK). Optical density of 11 
the bands was quantified using Image Pro Plus 7.0 software (MediaCybernetics, 12 
Bethesda, MD, USA), normalized and expressed as arbitrary units. 13 
2.4.2 Lipid extraction and endocannabinoid measurement 14 
Hemisected brains were dounce-homogenized and extracted with acetone 15 
containing internal deuterated standards for anandamide (AEA), 16 
palmitoylethanolamide (PEA), oleoylethanolamide (OEA) and 2-17 
arachidonoylglycerol (2-AG) quantification by isotope dilution LC-MS, i.e. 5 pmol 18 
d8-AEA, and 50 pmol d4-PEA, d4-OEA, and d5-2-AG, (Cayman Chemical), 19 
respectively. The lipid-containing organic phases were then purified by open bed 20 
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chromatography on silica and fractions were obtained by eluting the column with 1 
99:1, 90:10, and 50:50 (v/v) chloroform/methanol. Fractions eluted with 2 
chloroform/methanol 90:10 were collected, the excess solvent evaporated with a 3 
rotating evaporator, and aliquots analyzed by isotope dilution-LC/atmospheric 4 
pressure chemical ionization/MS carried out in the selected ion monitoring mode 5 
by using a Shimadzu HPLC apparatus (LC-10ADVP) coupled to a Shimadzu 6 
(LCMS-2020) quadrupole mass spectrometer via a Shimadzu atmospheric 7 
pressure chemical ionization interface. MS detection was performed by using 8 
values of m/z 356 and 348 (molecular ions + 1 for d8-AEA and AEA), m/z 304 9 
and 300 (molecular ions + 1 for d4-PEA and PEA), m/z 330 and 326 (molecular 10 
ions + 1 for d4-OEA and OEA) and m/z 384 and 379 (molecular ions +1 for d5-2-11 
AG and 2-AG). AEA, PEA, OEA, and 2-AG levels were therefore calculated on 12 
the basis of their area ratios with the internal deuterated standard signal areas. 13 
Lipid amounts expressed as pmol were then normalized per gram or milligram of 14 
wet tissue. 15 
2.4.3 Immunohistochemistry 16 
Frozen brain sections were obtained using a Leica cryostat CM1510 set to 20μm 17 
thickness and a −20°C chamber temperature. Sagittal sections were collected on 18 
gelatin-coated slides (4 sections per slide, 200μm apart) and permeabilized with 19 
100% methanol at -20°C for 30 minutes. After three washes in 0.05% Triton X-20 
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100 in TBS, sections were blocked with 3% normal goat serum in TBS for 1 hour 1 
at room temperature and then incubated overnight 4°C with rabbit anti-phospho-2 
rpS6 (Ser240/244) (1:50) from Cell Signaling Technology (Danvers, MA, USA) 3 
diluted in blocking solution. After blocking peroxidase activity with 0.3% H2O2 in 4 
TBS for 15 min, sections were washed in TBS and incubated for 4 hours at room 5 
temperature with goat anti-rabbit horseradish peroxidase (HRP) conjugated 6 
secondary antibody diluted 1:100 (Vector Labs, Burlingame, CA, USA). The 7 
sections were then incubated in chromogen 3,3’-diaminobenzidine 8 
tetrahydrochloride (DAB) for 5 min. The reaction was stopped in PBS, sections 9 
were dehydrated and cover slipped. 10 
Digital Images were captured using Retiga R1 CCD camera (QImaging, Surrey, 11 
BC, Canada) attached to an Olympus BX51 (Tokyo, Japan) polarizing/light 12 
microscope. Ocular imaging software (QImaging) was used to import images 13 
from the camera. Images of layer V neurons in the medial prefrontal cortex were 14 
acquired by first delineating the brain sections and the regions of interest (ROI) 15 
at low magnification (×4 objective) and the ROI were further refined under a ×40 16 
objective. Labeled cells were counted manually in every ten 20μm-thick sagittal 17 
section (200μm apart) within the ROI using a 300 × 300 μm grid as reference. 18 
Three mice per each experimental group (four sections/mouse) were analyzed 19 
blinded. 20 
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2.4.4 Nuclear size measurements 1 
For DAPI staining, slides were pre-incubated in 80% Methanol at 4°C for 5 min, 2 
washed in TBS for 10 min and then incubated in a working solution 1 to 10 in 3 
PBS from a 0.01% stock solution in the dark for 30 minutes at room temperature. 4 
After several washes in PBS, sections were dehydrated and cover slipped. 5 
Images of layer V neurons in the medial prefrontal cortex and of CA1 pyramidal 6 
cell layer were acquired using a ×20 objective after having defined the outlines of 7 
the regions of interest at low magnification (×4 objective). Outlines of nuclei were 8 
manually traced at ×20 image magnification using ImageJ software (NIH, 9 
Bethesda, MD, USA). Four slices of tissue from three animals per each 10 
experimental group (30–75 cells/animal) were analyzed blind to the treatment 11 
groups. Only in-focus neurons that were completely within the field of view and 12 
whose signal was not occluded by overlying cells were measured. 13 
2.5 Statistics 14 
The Shapiro–Wilk test was first used to determine if the data were normally 15 
distributed. Qualitative non-normally distributed score data were analyzed non-16 
parametrically using Pearson's Chi-square test with Yates correction. NOR data 17 
and biochemical results were expressed as mean ± SEM and analyzed by two-18 
way repeated measures and main effects ANOVA, respectively, by the GLM 19 
package of Statistica 7.0. Bonferroni’s post-hoc test was used to control for 20 
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multiple comparisons. Kaplan-Meier survival curves were generated and 1 
compared using a Dunnet-type log-rank method. The level of statistical 2 
significance was set at p<0.05. Calculations were carried out using Statistica 7.0 3 
and R (R Core Team, 2013) Statistical Software. 4 
3. Results 5 
3.1 Behavioral data 6 
3.1.1 Effect of chronic CBDV treatment on motor and neurological sign 7 
progression in Mecp2-deficient male mice 8 
Figure 1A shows the effect of chronic CBDV treatment on tremors, hind limb 9 
clasping, breathing, gait, mobility and general condition in KO mice over time. No 10 
symptoms were present in Mecp2 KO mice until 4 weeks of age (data not shown). 11 
Either WT mice treated with vehicle or CBDV did not show any symptom (score 12 
= 0) during the entire period of observation (data not shown). 13 
Male Mecp2 KO mice exhibited tremors beginning from 5 weeks of age. CBDV 14 
administration significantly reduced tremors in Mecp2 KO mice at 5 (χ2[8]3. 15 
=12.765, p=0.012) and 6 (χ2[8] =16.422, p=0.036) weeks of age, but not later. 16 
Doses of 2, 20 and 200 mg/kg showed similar efficacy (p<0.001) whereas the 17 
lowest dose of CBDV tested, 0.2 mg/kg, was ineffective. 18 
Mecp2 KO mice showed a significant increase in hind limb clasping starting from 19 
6 weeks of age. CBDV treatment significantly attenuated hind limb clasping in KO 20 
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mice at 6 weeks of age (χ2 [8]=22.814, p=0.0036). This effect was reached at 1 
doses of 2 (p>0.05), 20 (p<0.01) and 200 mg/kg (p<0.05). In contrast, CBDV was 2 
ineffective at the lowest dose tested, 0.2 mg/kg.  3 
Breathing and gait abnormalities were evident in Mecp2 KO mice starting from 7 4 
weeks of age. Breathing (χ2 [8]=22.405, p=0.0042) and gait (χ2 [8]=16.275, 5 
p=0.039) were improved by CBDV in Mecp2 KO mice at 7 weeks of age. CBDV 6 
treatment attenuated breathing abnormalities at doses of 2 (p<0.01), 20 (p<0.05) 7 
and 200 (p<0.05) mg/kg compared to KO-vehicle mice. Similarly, gait alterations 8 
were significantly reduced by CBDV treatment at doses of 2 (p<0.01), 20 (p<0.01) 9 
and 200 (p<0.001) mg/kg. Again, the lowest dose tested was completely 10 
ineffective. 11 
Impaired mobility and deterioration of general condition in KO mice was observed 12 
starting from 7 weeks of age. CBDV administration at all doses tested did not 13 
affect both parameters in KO mice during the whole treatment schedule. 14 
To gain an overall impression of CBDV treatment in Mecp2 KO mice over time, 15 
individual behavior scores were combined into a total symptom score for each 16 
mouse (figure 1B). Total symptom score was significantly increased in KO mice 17 
treated with vehicle starting from 5 weeks of age compared to WT mice and 18 
continued to increase until the end of the observation period. Significant effects 19 
were observed on total symptom score at 6 (χ2 [8]=19.617, p=0.0037) and 7 (χ2 20 
18 
 
[8]=21.732, p=0.0041) weeks of age. Treatment with CBDV 2, 20 and 200 mg/kg 1 
showed similar efficacy in attenuating motor and neurological deficits in KO mice. 2 
Indeed, they significantly improved total symptom score in KO mice at 6 3 
(p<0.001) and 7 (p<0.001) weeks of age, although CBDV’s beneficial effect was 4 
lost at later stages of the disease progression (i.e. 8 and 9 weeks of age). In 5 
contrast, CBDV 0.2 mg/kg did not affect the progression of symptoms over the 6 
entire observation period. 7 
3.1.2 Effect of chronic CBDV treatment on survival and body weight in Mecp2-8 
deficient male mice 9 
Survival data refer to all mice that underwent behavioral assessment. Figure 2A 10 
shows the percentage survival of Mecp2 KO and WT mice treated with CBDV or 11 
vehicle. The results are plotted as Kaplan–Meier survival curves and expressed 12 
as the percentage of surviving mice over total mice with respect to time for each 13 
experimental group. No lethality was observed in WT mice treated with either 14 
vehicle or CBDV. In contrast, survival in KO mice treated with vehicle was only 15 
38.5% by 9 weeks of age. All doses of CBDV showed a trend to increase survival 16 
rates in Mecp2 KO mice at the end of the observation period compared to vehicle-17 
treated littermates (KO-CBDV 0.2 mg/kg: 66.6%; KO-CBDV 2 mg/kg: 61.5%; KO-18 
CBDV 20 mg/kg: 71.4%; KO-CBDV 200 mg/kg: 87.5%), although this effect 19 
19 
 
reached statistical significance only at the highest dose tested, 200 mg/kg 1 
(p=0.0433; log Rank test). 2 
Regarding body weight, as expected, Mecp2 KO mice were significantly leaner 3 
than WT littermates (figure 2B). Chronic CBDV administration did not recover 4 
body weight in KO mice, although a post-hoc test did not reveal significant 5 
differences between WT-vehicle and KO mice treated with CBDV 2/20/200 6 
mg/kg. 7 
3.1.3 Effect of chronic CBDV treatment on recognition memory deficits in Mecp2-8 
deficient male mice 9 
Figure 3 shows the effect of chronic CBDV administration on short-term 10 
recognition memory at PND 41, 56 and 66. No differences in exploratory behavior 11 
and locomotor activity were observed in WT and KO mice during the training 12 
session of the recognition memory test (Supplementary Figure S2). Exploration 13 
times of the novel object and the familiar object in the test phase are reported in 14 
Supplementary Figure S3. Repeated measures ANOVA with time as the 15 
dependent variable revealed significant main effects of genotype (F[1-244]=111.5, 16 
p<0.0001), treatment (F[4-244]=47.77, p<0.0001) and genotype x treatment 17 
interaction (F[8-244]=4.152, p=0.0440) on recognition memory. A cognitive 18 
impairment in recognition memory was consistently present in KO mice and was 19 
maintained until adulthood. KO animals showed significant reductions of the 20 
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discrimination index at PND 41 (p<0.001), 56 (p<0.001) and 66 (p<0.001) 1 
compared to WT mice. At each time point, administration of CBDV 2, 20 and 200 2 
mg/kg significantly counteracted the cognitive impairment in recognition memory 3 
present in KO mice (p<0.001). In contrast, chronic CBDV treatment at the lowest 4 
dose tested, 0.2 mg/kg, did not rescue the cognitive impairment in KO mice. 5 
3.2 Biochemical data 6 
3.2.1 Effect of chronic CBDV treatment on BDNF, IGF-1 protein levels and 7 
downstream PI3K/AKT/mTOR and ERK1/2 pathways in hemisected brains of 8 
Mecp2-deficient male mice 9 
CBDV at all doses tested did not affect the expression of all the considered 10 
biochemical markers when given chronically to WT mice. 11 
Statistical analysis showed significant effects of genotype (F[1,38]=5.677, 12 
p=0.0220), treatment (F[4,38]=2.677, p=0.0455) and genotype x treatment 13 
interaction (F[4,38]=9.997, p=0.0081) on BDNF expression. BDNF protein levels 14 
were significantly reduced in Mecp2 KO mice treated with vehicle or CBDV 0.2 15 
mg/kg with respect to WT littermates (p<0.01; p<0.05 respectively). In contrast, 16 
2, 20 and 200 mg/kg CBDV significantly restored BDNF levels in KO mice, to a 17 
similar degree (p<0.05; Figure 4A). 18 
Two-way ANOVA analysis revealed significant effects of genotype (F[1,38]=4.773, 19 
p=0.0032) and genotype x treatment interaction (F[4,38]=2.709, p=0.0444) on IGF-20 
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1 levels. IGF-1 levels were significantly reduced in Mecp2 KO mice treated with 1 
vehicle compared to WT animals (p<0.05). CBDV significantly increased IGF-1 2 
levels in KO mice at doses of 2 (p<0.05), 20 (p<0.05) and 200 (p<0.01) mg/kg 3 
(Figure 4A). 4 
A significant genotype x treatment interaction (F[4,26]=6.574, p=0.0009) and a 5 
trend for genotype effect (F[1,26]=3.967, p=0.0570) were found on pAKT levels 6 
(figure 4B). pAKT was significantly reduced in Mecp2 KO mice treated with 7 
vehicle compared to WT-vehicle animals (p<0.05). Chronic CBDV administration 8 
dose dependently recovered pAKT levels in Mecp2 deficient mice, reaching 9 
statistical significance at doses of 20 (p<0.01) and 200 (p<0.001) mg/kg. 10 
Significant effects of genotype (F[1,29]=23.83, p<0.0001) and genotype x treatment 11 
interaction (F[4,29]=2.702, p=0.0500) on rpS6 phosphorylation were also 12 
observed. Mecp2 deletion significantly reduced rpS6 phosphorylation within the 13 
adult brain (p<0.001). Chronic CBDV treatment significantly increased rpS6 14 
phosphorylation levels in KO mice compared to vehicle-treated mutants at doses 15 
of 2 (p<0.05), 20 (p<0.01) and 200 (p<0.05) mg/kg. 16 
Immunohistochemical analysis revealed significant effects of genotype 17 
(F[1,20]=12.07; p=0.0024), treatment (F[4,20]=3.042; p=0.0413) and genotype x 18 
treatment interaction (F[4,20]=7.156; p=0.0010) on rpS6 phosphorylation in layer V 19 
neurons of the medial prefrontal cortex (figure 4C). Indeed, rpS6 phosphorylation 20 
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was significantly decreased in Mecp2 KO mice compared to WT animals 1 
(p<0.05); CBDV administration significantly enhanced rpS6 phosphorylation in 2 
mutant mice at doses of 20 (p<0.05) and 200 (p<0.01) mg/kg without affecting its 3 
levels in WT animals. A trend towards an enhancement of rpS6 phosphorylation 4 
was also present in KO mice after administration of the 2 mg/kg dose (p=0.0717) 5 
whereas the 0.2 mg/kg dose was completely ineffective. 6 
Finally, neither genotype nor CBDV treatment affected ERK1/2 phosphorylation 7 
(figure 4B). 8 
3.2.2 CBDV effect on nuclear areas in Layer V neurons of the medial prefrontal 9 
cortex and in the CA1 layer of the hippocampus 10 
In the mPFC, the mean nuclear area of KO neurons was 35.5% smaller than that 11 
of WT neurons (WT-vehicle = 69.98 ± 2.091 μm2, KO-vehicle = 45.10 ± 1.208 12 
μm2; p<0.001, Figure 5A). CBDV treatment, at all doses tested, did not affect 13 
nuclear size in KO neurons (CBDV 0.2 mg/kg = 40.48 ± 1.598 μm2, CBDV 2 14 
mg/kg = 47.71 ± 1.779 μm2, CBDV 20 mg/kg = 48.44 ± 1.782 μm2, CBDV 200 15 
mg/kg = 53.08 ± 2 μm2). In the CA1 layer of the hippocampus, the mean nuclear 16 
area of KO neurons was 32.3% smaller than that of WT neurons (WT-vehicle = 17 
63.5 ± 2.237 μm2, KO-vehicle = 43.0 ± 1 μm2; p<0.001, Figure 5B). A partial 18 
rescue of hippocampal neurons nuclear size was observed in KO mice after 19 
chronic CBDV administration at doses of 2, 20 and 200 mg/kg (CBDV 2 mg/kg = 20 
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53.46 ± 1.721 μm2, CBDV 20 mg/kg = 52.55 ± 1.982 μm2, CBDV 200 mg/kg = 1 
51.66 ± 1.650 μm2), but not 0.2 mg/kg (CBDV 0.2 mg/kg = 47.26 ± 1.862 μm2).  2 
3.2.3 Effect of chronic CBDV treatment on cannabinoid CB1 and CB2 receptors 3 
in Mecp2-deficient male mice 4 
Two-way ANOVA analysis revealed significant effects of genotype and genotype 5 
x treatment interaction on CB1 (F[1,32]=19.89, p<0.0001; F[4,32]=3.429, p=0.0193) 6 
and CB2 (F[1,32]=4.662, p=0.0384; F[4,32]=3.834, p=0.0118) receptors (figure 6). 7 
CB1 levels were significantly increased in Mecp2 KO mice treated with vehicle 8 
compared to WT-vehicle littermates (p<0.001). Chronic CBDV treatment 9 
significantly reduced CB1 receptor expression in KO mice at doses of 2 (p<0.05), 10 
20 (p<0.05) and 200 (p<0.05) mg/kg. CBDV at all doses tested did not affect CB1 11 
receptor levels when chronically administered to WT animals. CB2 receptor 12 
expression was significantly enhanced in Mecp2 KO mice treated with vehicle 13 
compared to WT-vehicle controls (p<0.001). Chronic CBDV administration 14 
significantly rescued CB2 receptor expression in KO mice at doses of 2 15 
(p<0.001), 20 (p<0.001) and 200 (p<0.001) mg/kg, without affecting its levels in 16 
WT littermates. 17 
3.2.4 Effect of chronic CBDV treatment on endocannabinoid contents in Mecp2-18 
deficient male mice 19 
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No statistically significant differences in AEA, OEA PEA and 2-AG levels were 1 
found between the two genotypes, although a trend for the increase of AEA 2 
(p=0.0613) and OEA (p=0.0817) was noticed in KO mice (figure 7A). Statistical 3 
analysis revealed significant effects of genotype x CBDV treatment interaction on 4 
AEA (F[4,20]=5.859, p=0.045) and 2-AG (F[4,20]=5.375, p=0.041) levels as well as 5 
non-significant trend on OEA (F[4,20]=8.787, p=0.067) content. CBDV 6 
administration at doses of 2 (p<0.05), 20 (p<0.001) and 200 (p<0.01) mg/kg 7 
significantly increased AEA levels in Mecp2 KO mice with respect to WT-vehicle 8 
mice. A similar effect of CBDV was also observed on OEA levels. Indeed, CBDV 9 
at 2 (p<0.01), 20 (p<0.001) and 200 (p<0.05) mg/kg significantly enhanced OEA 10 
content. Chronic CBDV administration significantly reduced 2-AG levels in the 11 
brain of KO mice at doses of 20 (p<0.05) and 200 (p<0.01) mg/kg compared to 12 
vehicle-treated animals. CBDV treatment also showed a trend toward reduction 13 
of 2-AG levels in WT mice. Finally, CBDV treatment did not affect PEA content in 14 
the brain of both WT and KO animals. 15 
3.2.5 Effect of chronic CBDV treatment on endocannabinoid synthetic and 16 
degrading enzymes in Mecp2-deficient male mice 17 
Two-way ANOVA analysis revealed significant effects on NAPE-PLD (genotype, 18 
F[1,32]=5.724, p=0.0228; genotype x treatment interaction, F[4,32]=3.227, 19 
p=0.0247), FAAH (genotype, F[1,32]=11.14, p=0.0022; treatment, F[4,32]=1.782, 20 
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p=0.1576) and DAGLα (treatment, F[4,32]=11.75, p<0.0001) levels in the brains of 1 
KO mice (figure 7B). The expression of the main AEA synthetic enzyme NAPE-2 
PLD was significantly increased in male Mecp2 KO mice after chronic treatment 3 
with CBDV at the highest dose tested (p<0.01). In contrast, CBDV treatment at 4 
the lowest doses did not affect NAPE-PLD levels both in Mecp2 WT and KO mice. 5 
Deletion of Mecp2 resulted in a significant reduction of FAAH levels (p<0.05) that 6 
were not rescued by chronic CBDV administration. In addition, chronic treatment 7 
with CBDV showed a trend towards a reduction in FAAH expression in WT mice 8 
at doses of 0.2 and 20 mg/kg. CBDV treatment also affected the expression of 9 
DAGLα, a key enzyme in the biosynthesis of the endocannabinoid 2-AG. In fact, 10 
chronic CBDV administration significantly reduced DAGLα protein levels at all 11 
doses tested both in WT (p<0.01) and in KO (p<0.001) mice. No effect of either 12 
genotype or CBDV treatment was observed on the 2-AG degrading enzyme MAG 13 
lipase. 14 
3.2.6 Protein levels of BDNF, p-rpS6, endocannabinoid receptors and enzymes 15 
in the brain of pre-symptomatic 4-week-old mice 16 
In order to establish whether the expression of BDNF, p-rpS6 as well as 17 
endocannabinoid receptors and synthetic/degrading enzymes was altered in an 18 
apparently asymptomatic phase of the phenotype progression, we performed 19 
Western blot analysis in brain lysates from 4-week-old WT and KO mice, i.e. 20 
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before starting CBDV treatment. As reported in supplementary figure S4, both 1 
BDNF and rpS6 phosphorylation levels were significantly reduced in 4-week-old 2 
Mecp2-null mice compared to WT animals by about 48.3% and 35.9% 3 
respectively. In contrast, no alteration in the expression of CB1 and CB2 4 
receptors was present at this stage of the phenotype progression. Similarly, no 5 
changes were found in the main endocannabinoid synthetic and degrading 6 
enzymes, although a trend towards a reduction in MAG lipase expression was 7 
present (p=0.0805). 8 
4. Discussion 9 
Chronic administration of the non-psychotomimetic phytocannabinoid CBDV 10 
completely recovers recognition memory deficits in Mecp2 KO animals and this 11 
improvement persists at advanced stages of the phenotype progression. 12 
Furthermore, CBDV prolongs survival and delays the appearance of neurological 13 
and motor signs in Mecp2 KO mice in a time window between 6 and 7 weeks of 14 
age. This last effect is in line with previous findings by Vigli et al. (2018) showing 15 
that 14 days of treatment with similar doses of CBDV improves the general health 16 
status, the social sphere and the motor skills in MeCP2-308 male mice. However, 17 
our study provides additional information supporting that CBDV’s beneficial effect 18 
on motor and neurological signs is only transient and is lost when a longer 19 
treatment schedule (5 weeks long) is applied. Thus, the effect of CBDV might be 20 
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explained better as a delay in the onset of the neurological defects rather than a 1 
reduction in their intensity at a specific age. 2 
From a pharmacological point of view, CBDV does not show a linear dose-3 
response curve but it elicits an “all-or-none” response, as doses of 2, 20 and 200 4 
mg/kg show similar efficacy in ameliorating the phenotype of Mecp2 mutant mice, 5 
whereas the lowest dose tested, 0.2 mg/kg, is completely ineffective. Although a 6 
steep dose-response effect might exist between 0.2 and 2 mg/kg, CBDV’s non-7 
linear dose response curve could be a consequence of drug tolerance following 8 
repeated exposure or target desensitization. However, a final explanation must 9 
await the identification of the specific target responsible for CBDV’s effects in this 10 
model. In addition, we cannot rule out the possibility that CBD content in our 11 
preparation, which is primarily CBDV (96.4%), but also contains low levels of CBD 12 
(3.6%), might have affected CBDV pharmacokinetics. In fact, different dose-13 
response curves can be observed when cannabinoids are administered in 14 
isolation or in combinations that contain also low levels of other 15 
phytocannabinoids (Gallily et al., 2015; Zuardi et al., 2017). 16 
Also, we cannot exclude that CBD could participate in the overall effects of drug 17 
treatment reported in this study, as significant neuroprotective effects of this 18 
phytocannabinoid were reported in conditions including depression, anxiety, 19 
stroke and neurodegenerative diseases even at very low doses (Campos et al., 20 
28 
 
2017; Crippa et al., 2018) and low doses of CBD improved cognition, motor 1 
activity and BDNF levels in animal models (Avraham et al.,2011; Magen et al., 2 
2010). 3 
Biochemical studies performed at an advanced stage of the phenotype shows 4 
that CBDV treatment simultaneously elevates the levels of BDNF and IGF-1 in 5 
the brain of clearly symptomatic Mecp2 KO mice at behaviorally efficacious 6 
doses.  7 
Expression of BDNF is decreased in mouse models of RTT (Chang et al., 2006; 8 
Chen et al., 2003; Li and Pozzo-Miller, 2014; Martinowich et al., 2003) and 9 
enhancement of BDNF levels in vivo relieves some symptoms of the mutant 10 
phenotype (Chang et al., 2006; Deogracias et al., 2012; Johnson et al., 2012; 11 
Kline et al., 2010; Kron et al., 2014; Ogier et al., 2007; Roux et al., 2012; Schmid 12 
et al., 2012). Unfortunately, the therapeutic potential of BDNF is limited by its poor 13 
efficiency at crossing the blood–brain barrier (Pardridge et al., 1994). Hence, 14 
possible therapeutic strategies must rely on the identification of agents capable 15 
of indirectly stimulating BDNF levels. Remarkably, our data support CBDV 16 
potential to modulate BDNF levels in Mecp2-null mice. 17 
CBDV treatment also increases IGF-1 levels in the brain of mutant mice. IGF-1 18 
is another neurotrophic factor that holds great promise as therapeutic agent in 19 
RTT. Like BDNF, IGF-1 is widely expressed in the brain during development 20 
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(Dyer et al., 2016). In mouse models, administration of both IGF-1 and its 1 
truncated form (1-3)IGF-1 reverses many of the features of the RTT phenotype 2 
(Castro et al., 2014; Chen and Russo-Neustadt, 2007; Della Sala et al., 2016; 3 
Tropea et al., 2009) and early studies in RTT patients have demonstrated the 4 
tolerability and safety of IGF-1 as a potential treatment (Khwaja et al., 2014; Pini 5 
et al., 2016; Pini et al., 2014; Pini et al., 2012). 6 
Although both BDNF and IGF-1 signal via PI3K/AKT and MAPK/ERK pathways 7 
to affect neuronal maturation and survival (Tropea et al., 2006; Yoshii and 8 
Constantine-Paton, 2007; Zheng and Quirion, 2004), there is direct evidence of 9 
the involvement of the AKT pathway in RTT. Reduced phosphorylation of rpS6 in 10 
Mecp2 deficient mice is specific to signaling via AKT and not ERK1/2 kinases 11 
(Ricciardi et al., 2011). Worth noting, CBDV-mediated increases of BDNF and 12 
IGF-1 are associated with the normalization of their common downstream 13 
AKT/mTOR signaling pathway whereas no effects of either genotype or CBDV 14 
treatment are observed on ERK1/2 expression. Interestingly, reduced 15 
phosphorylation of rpS6 in Mecp2 deficient mice is most intense in the mPFC, in 16 
line with recent studies supporting a contribution of mPFC hypofunction to the 17 
development of RTT-like phenotypes (Howell et al., 2018; Sceniak et al., 2016). 18 
In particular, excitatory hypoconnectivity in the mPFC has been linked to cognitive 19 
impairments in Mecp2 mutant mice (Howell et al., 2018) possibly suggesting that 20 
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CBDV’s ability to normalize rpS6 phosphorylation in the mPFC could contribute 1 
to its beneficial effect on memory impairments. Consistent with this hypothesis, 2 
the normalization of PI3K/AKT/mTOR pathway after CBDV administration is 3 
observed at a time point when CBDV is still recovering memory deficits but is no 4 
longer effective towards motor and neurological signs (i.e. 9 weeks of age). 5 
As reduction of nuclear volumes represents a consistent feature of Mecp2 6 
deficiency at the cellular level (Gadalla et al., 2013; Giacometti et al., 2007), we 7 
assessed whether CBDV treatment could affect this parameter. Analysis of 8 
nuclear volumes indicates that CBDV did not rescue nuclear size in the layer V 9 
of the mPFC and only a partial effect was observed in the CA1 area of the 10 
hippocampus of Mecp2 mutant mice, suggesting CBDV’s inability to recover this 11 
morphological alteration at least at the end of the treatment schedule. 12 
A previous study found increased levels of GPR55 receptor in RTT mouse 13 
hippocampus (Vigli et al., 2018), hence we here checked for possible changes 14 
on other components of the endocannabinoid system. Interestingly, the 15 
expression of brain CB1 and CB2 receptors is up-regulated in Mecp2 deficient 16 
mice and chronic CBDV treatment at doses of 2, 20 and 200 mg/kg significantly 17 
normalized the levels of both receptors at this advanced stage of the phenotype 18 
progression. Given that CBDV binds to CB1 and CB2 receptors with very weak 19 
affinity (Amada et al., 2013; Hill et al., 2012a; Hill et al., 2013; Iannotti et al., 2014; 20 
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Rosenthaler et al., 2014), we hypothesize that normalization of CB1 receptor 1 
expression following CBDV treatment in Mecp2 KO mice might occur indirectly 2 
as a consequence of its ability to modulate endocannabinoid signaling, namely 3 
by increasing AEA levels and hence down-regulating cannabinoid receptor 4 
expression. Indeed, chronic CBDV administration at doses of 2, 20 and 200 5 
mg/kg increased AEA levels and elevates OEA content in Mecp2 mutant mice, 6 
effects that are associated with reduced FAAH expression and, only for the 7 
highest dose tested, i.e. 200 mg/kg, with enhancement of NAPE-PLD expression. 8 
Furthermore, CBDV greatly reduced 2-AG levels both in WT and KO mice. This 9 
effect might be exerted at least in part via reduction of DAGLα expression, 10 
although the doses that were more efficacious at reducing 2-AG levels were also 11 
the ones least efficacious at exerting this effect. It is possible that CBDV reduces 12 
2-AG levels also via its previously reported ability to inhibit DAGLα activity in vitro 13 
(Bisogno et al., 2003; De Petrocellis et al., 2011). Thus, in our experimental 14 
conditions CBDV is associated with enhancement of AEA and OEA levels likely 15 
through inhibition of FAAH and reduction of 2-AG, possibly in part through 16 
inhibition of DAGLα. 17 
Up-regulation of CB1 and CB2 receptors and down-regulation of FAAH levels 18 
were also present in naïve 9-week-old Mecp2 KO mice (see supplementary figure 19 
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S5), indicating that these changes did not arise from chronic handling procedure 1 
(Sciolino et al., 2010). 2 
It is not possible from our data to draw any conclusion as to whether alterations 3 
of the endocannabinoid system in Mecp2 mutant mice sustain the phenotype or 4 
represent a compensatory mechanism. Similarly, further studies are needed in 5 
order to assess whether CBDV effects on the components of the 6 
endocannabinoid (AEA and 2-AG) and endocannabinoid-related (OEA) signaling 7 
systems are a mere consequence or, instead, contribute to its therapeutic effect. 8 
The observation that, unlike BDNF and p-rpS6, endocannabinoid receptors and 9 
endocannabinoid enzymatic machinery are not altered in the brain of apparently 10 
asymptomatic 4-week-old Mecp2 KO mice possibly suggests that the expression 11 
of the different components of the endocannabinoid system could be dynamically 12 
regulated during phenotype progression in Mecp2 KO mice. However, any 13 
conclusion on the role of the endocannabinoid system in this animal model must 14 
await the investigation of the effects of drugs specifically targeting the single 15 
components of the system both at baseline and following CBDV treatment.  16 
Two major limitations should be taken into account when interpreting results from 17 
this study. First, Western blot experiments were carried out on hemibrains rather 18 
than discrete brain regions and future studies must test the molecular alterations 19 
in different brain structures to determine whether these changes are universal or 20 
33 
 
brain region-specific. Second, all the neurochemical characterizations have been 1 
performed at the end of CBDV treatment, when the compound was still effective 2 
in recovering cognitive deficits but no longer beneficial towards neurological and 3 
motor signs. Thus, it cannot be excluded that different modifications could have 4 
been observed as a consequence of CBDV administration if the same analysis 5 
would have been carried out at earlier time points (i.e. at 7 weeks of age when 6 
CBDV showed efficacy also towards neurological and motor signs). Accordingly, 7 
when biochemical investigations were performed at an early symptomatic stage 8 
of the disease they failed to reveal any defect on BDNF and IGF1 levels as well 9 
as on the phosphorylation level of the rpS6 in the brain of MeCP2-308 mice 10 
treated with either vehicle or CBDV (Vigli et al., 2018). Importantly, our data 11 
obtained at this advanced stage of the disease highlight that CBDV treatment can 12 
normalize BDNF/IGF1 levels as well as the defective PI3K/AKT/mTOR pathway 13 
in Mecp2 mutant mice, possibly contributing to the restoration of cognitive deficits. 14 
Despite these limitations, this paper demonstrate that chronic CBDV 15 
administration exerts an enduring and complete rescue of recognition memory 16 
deficits in Mecp2 mutant mice, an effect that is associated with the normalization 17 
of BDNF, IGF-1 and rpS6 phosphorylation levels as well as CB1 and CB2 18 
receptor expression. Regarding neurological and motor signs, our data support 19 
previous findings indicating that CBDV can ameliorate neurological and motor 20 
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signs during an early symptomatic phase of the disease (Vigli et al., 2018) but 1 
highlight that this effect is only transient and is lost at advanced stages of the 2 
phenotype progression. 3 
As a whole, available evidence encourages the investigation of the molecular 4 
mechanism(s) by which CBDV can affect behavioral and molecular parameters 5 
in this animal model as well as a more specific evaluation of CBDV’s efficacy in 6 
female models of RTT-like symptoms. 7 
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Figure legends 1 
Figure 1: Effect of chronic CBDV (0.2, 2, 20, 200 mg/kg/day, weeks 5-9) 2 
treatment on the Mecp2 KO phenotype. (A) “Score Test” for tremor, hindlimb 3 
clasping, breathing, gait, mobility and general condition in Mecp2 KO mice. 4 
Animals were scored (from 0 to 2) every other day and score data represent the 5 
weekly average of four-day observations in each corresponding week for each 6 
symptom considered. (B) Total symptom scores in vehicle- and CBDV-treated 7 
Mecp2 KO mice. Data represent mean ± SEM of 22 WT-vehicle, 10 WT-CBDV 8 
0.2 mg/kg, 13 WT-CBDV 2 mg/kg, 12 WT-CBDV 20 mg/kg, 3 WT-CBDV 200 9 
mg/kg, 11 KO-vehicle, 6 KO-CBDV 0.2 mg/kg, 13 KO-CBDV 2 mg/kg, 14 KO-10 
CBDV 20 mg/kg, 8 KO-CBDV 200 mg/kg and were analyzed using Pearson’s Chi 11 
square test with Yates correction. *p<0.05, **p<0.01, ***p<0.001 vs KO-vehicle 12 
mice. 13 
Figure 2: (A) Effect of chronic CBDV (0.2, 2, 20, 200 mg/kg/day, weeks 5-9) 14 
treatment on survival in Mecp2 KO mice. Kaplan-Meier survival curves of CBDV-15 
treated Mecp2 KO mice compared to KO-vehicle littermates (p=0.0183, Kaplan–16 
Meier log-rank test). The table summarizes the n number of KO mice in each 17 
considered week. (B) Area under the curve (AUC) for body weight recorded daily 18 
during the whole treatment schedule. Data are expressed as mean ± SEM 22 19 
WT-vehicle, 10 WT-CBDV 0.2 mg/kg, 13 WT-CBDV 2 mg/kg, 12 WT-CBDV 20 20 
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mg/kg, 3 WT-CBDV 200 mg/kg, 11 KO-vehicle, 6 KO-CBDV 0.2 mg/kg, 13 KO-1 
CBDV 2 mg/kg, 14 KO-CBDV 20 mg/kg, 8 KO-CBDV 200 mg/kg and were 2 
analyzed using a two-way ANOVA followed by Tukey’s multiple comparison test. 3 
*p<0.05 vs WT-vehicle mice. 4 
Figure 3: Effect of chronic CBDV (0.2, 2, 20, 200 mg/kg/day, weeks 5-9) 5 
treatment on recognition memory in WT and KO mice as measured through the 6 
NOR test at PND 41, 56 and 66. Data are expressed as mean ± S.E.M. of 22 WT-7 
vehicle, 10 WT-CBDV 0.2 mg/kg, 13 WT-CBDV 2 mg/kg, 12 WT-CBDV 20 mg/kg, 8 
3 WT-CBDV 200 mg/kg, 11 KO-vehicle, 6 KO-CBDV 0.2 mg/kg, 13 KO-CBDV 2 9 
mg/kg, 14 KO-CBDV 20 mg/kg, 8 KO-CBDV 200 mg/kg and were analyzed by 10 
two-way repeated measures ANOVA (genotype and treatment as between 11 
factors and time as within factor) followed by Tukey’s multiple comparison test. 12 
*p<0.05, **p<0.01, ***p<0.001 vs WT-vehicle; °°°p<0.001 vs KO-vehicle. 13 
Figure 4: Effect of chronic CBDV treatment on protein levels of (A) BDNF and 14 
IGF-1, and (B) p-Akt (Ser473), its downstream effector p-rpS6 (Ser240/244), and 15 
ERK1/2 phosphorylation in the brains of Mecp2 WT and KO mice. Measurements 16 
were carried out on total protein lysates from hemisected brains. Representative 17 
blot images correspond to the results of one experiment out of four. Data are 18 
expressed as mean ± SEM of 3-5 animals per group and were analyzed by two-19 
way ANOVA followed by Tukey’s multiple comparison test. *p<0.05, **p<0.01, 20 
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***p<0.001 vs WT-vehicle; °p<0.05, °°p<0.01; °°°p<0.001 vs KO-vehicle. (C) n. 1 
of p-rpS6(Ser240/244)-positive neurons in layer V of the mPFC as quantified 2 
through immunohistochemistry. Data represent mean ± SEM of three animals per 3 
each experimental group (four slices /animal) and were analyzed by two-way 4 
ANOVA followed by Tukey’s multiple comparison test. *p<0.05 vs WT-vehicle; 5 
°p<0.05, °°p<0.01 vs KO-vehicle. (D) Representative high magnification (40x) 6 
views of p-rpS6 (Ser240/244) immunolabeling in layer V neurons of the mPFC in 7 
9-week-old Mecp2 WT and KO animals either treated with vehicle of CBDV 8 
(Scale bar = 50μm). 9 
Figure 5: Nuclear volume measurements of DAPI-labeled nuclei in the layer V of 10 
the mPFC (A) and (B) CA1 region of the hippocampus in Mecp2 KO and WT 11 
mice after chronic CBDV administration. Bar plots show mean nuclear volumes 12 
± SEM of three animals per each experimental group (four slices/30-75 13 
cells/animal). Statistical analysis was carried out by two-way ANOVA and Tukey’s 14 
multiple comparison test. *p<0.05, **p<0.01, ***p<0.001 vs WT-vehicle; °p<0.05 15 
vs KO-vehicle. 16 
Figure 6: Effect of chronic CBDV treatment on (A) protein levels of CB1 and CB2 17 
cannabinoid receptors in hemisected brains of Mecp2 WT and KO mice. (B) 18 
Representative blot images correspond to the results of one experiment out of 19 
four. Data are expressed as mean ± SEM of 3-6 animals per group and were 20 
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analyzed by two-way ANOVA followed by Tukey’s multiple comparison test. 1 
*p<0.05, **p<0.01, ***p<0.001 vs WT-vehicle; °p<0.05, °°p<0.01; °°°p<0.001 vs 2 
KO-vehicle. 3 
Figure 7: Effect of chronic CBDV treatment on (A) AEA, 2-AG, PEA and OEA 4 
contents and (B) protein levels of the main endocannabinoid synthetic and 5 
degrading enzymes NAPE-PLD, DAGLα, FAAH and MAGL in hemisected brains 6 
of Mecp2 WT and KO mice. Representative blot images correspond to the results 7 
of one experiment out of four. Data are expressed as mean ± SEM of 3-6 animals 8 
per group and analyzed by two-way ANOVA followed by Tukey’s multiple 9 
comparison test. *p<0.05, **p<0.01, ***p<0.001 vs WT-vehicle; °p<0.05, 10 
°°p<0.01; °°°p<0.001 vs KO-vehicle. 11 
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Figure 1: Effect of chronic CBDV (0.2, 2, 20, 200 mg/kg/day, weeks 5-9) treatment on the Mecp2 KO 
phenotype. (A) “Score Test” for tremor, hindlimb clasping, breathing, gait, mobility and general condition in 
Mecp2 KO mice. Animals were scored (from 0 to 2) every other day and score data represent the weekly 
average of four-day observations in each corresponding week for each symptom considered. (B) Total 
symptom scores in vehicle- and CBDV-treated Mecp2 KO mice. Data represent mean ± SEM of 22 WT-
vehicle, 10 WT-CBDV 0.2 mg/kg, 13 WT-CBDV 2 mg/kg, 12 WT-CBDV 20 mg/kg, 3 WT-CBDV 200 mg/kg, 
11 KO-vehicle, 6 KO-CBDV 0.2 mg/kg, 13 KO-CBDV 2 mg/kg, 14 KO-CBDV 20 mg/kg, 8 KO-CBDV 200 
mg/kg and were analyzed using Pearson’s Chi square test with Yates correction. *p<0.05, **p<0.01, 
***p<0.001 vs KO-vehicle mice. 
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Figure 2: (A) Effect of chronic CBDV (0.2, 2, 20, 200 mg/kg/day, weeks 5-9) treatment on survival in Mecp2 
KO mice. Kaplan-Meier survival curves of CBDV-treated Mecp2 KO mice compared to KO-vehicle littermates 
(p=0.0183, Kaplan–Meier log-rank test). The table summarizes the n number of KO mice in each considered 
week. (B) Area under the curve (AUC) for body weight recorded daily during the whole treatment schedule. 
Data are expressed as mean ± SEM 22 WT-vehicle, 10 WT-CBDV 0.2 mg/kg, 13 WT-CBDV 2 mg/kg, 12 WT-
CBDV 20 mg/kg, 3 WT-CBDV 200 mg/kg, 11 KO-vehicle, 6 KO-CBDV 0.2 mg/kg, 13 KO-CBDV 2 mg/kg, 14 
KO-CBDV 20 mg/kg, 8 KO-CBDV 200 mg/kg and were analyzed using a two-way ANOVA followed by Tukey’s 
multiple comparison test. *p<0.05 vs WT-vehicle mice. 
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Figure 3: Effect of chronic CBDV (0.2, 2, 20, 200 mg/kg/day, weeks 5-9) treatment on recognition memory 
in WT and KO mice as measured through the NOR test at PND 41, 56 and 66. Data are expressed as mean 
± S.E.M. of 22 WT-vehicle, 10 WT-CBDV 0.2 mg/kg, 13 WT-CBDV 2 mg/kg, 12 WT-CBDV 20 mg/kg, 3 WT-
CBDV 200 mg/kg, 11 KO-vehicle, 6 KO-CBDV 0.2 mg/kg, 13 KO-CBDV 2 mg/kg, 14 KO-CBDV 20 mg/kg, 8 
KO-CBDV 200 mg/kg and were analyzed by two-way repeated measures ANOVA (genotype and treatment 
as between factors and time as within factor) followed by Tukey’s multiple comparison test. *p<0.05, 
**p<0.01, ***p<0.001 vs WT-vehicle; °°°p<0.001 vs KO-vehicle. 
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Figure 4: Effect of chronic CBDV treatment on protein levels of (A) BDNF and IGF-1, and (B) p-Akt (Ser473), 
its downstream effector p-rpS6 (Ser240/244), and ERK1/2 phosphorylation in the brains of Mecp2 WT and 
KO mice. Measurements were carried out on total protein lysates from hemisected brains. Representative 
blot images correspond to the results of one experiment out of four. Data are expressed as mean ± SEM of 
3-5 animals per group and were analyzed by two-way ANOVA followed by Tukey’s multiple comparison test. 
*p<0.05, **p<0.01, ***p<0.001 vs WT-vehicle; °p<0.05, °°p<0.01; °°°p<0.001 vs KO-vehicle. (C) n. of 
p-rpS6(Ser240/244)-positive neurons in layer V of the mPFC as quantified through immunohistochemistry. 
Data represent mean ± SEM of three animals per each experimental group (four slices /animal) and were 
analyzed by two-way ANOVA followed by Tukey’s multiple comparison test. *p<0.05 vs WT-vehicle; 
°p<0.05, °°p<0.01 vs KO-vehicle. (D) Representative high magnification (40x) views of p-rpS6 
(Ser240/244) immunolabeling in layer V neurons of the mPFC in 9-week-old Mecp2 WT and KO animals 
either treated with vehicle of CBDV (Scale bar = 50μm). 
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Figure 5: Nuclear volume measurements of DAPI-labeled nuclei in the layer V of the mPFC (A) and (B) CA1 
region of the hippocampus in Mecp2 KO and WT mice after chronic CBDV administration. Bar plots show 
mean nuclear volumes ± SEM of three animals per each experimental group (four slices/30-75 cells/animal). 
Statistical analysis was carried out by two-way ANOVA and Tukey’s multiple comparison test. *p<0.05, 
**p<0.01, ***p<0.001 vs WT-vehicle; °p<0.05 vs KO-vehicle. 
194x254mm (300 x 300 DPI) 
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Figure 6: Effect of chronic CBDV treatment on (A) protein levels of CB1 and CB2 cannabinoid receptors in 
hemisected brains of Mecp2 WT and KO mice. (B) Representative blot images correspond to the results of 
one experiment out of four. Data are expressed as mean ± SEM of 3-6 animals per group and were analyzed 
by two-way ANOVA followed by Tukey’s multiple comparison test. *p<0.05, **p<0.01, ***p<0.001 vs WT-
vehicle; °p<0.05, °°p<0.01; °°°p<0.001 vs KO-vehicle. 
91x63mm (300 x 300 DPI) 
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Figure 7: Effect of chronic CBDV treatment on (A) AEA, 2-AG, PEA and OEA contents and (B) protein levels 
of the main endocannabinoid synthetic and degrading enzymes NAPE-PLD, DAGLα, FAAH and MAGL in 
hemisected brains of Mecp2 WT and KO mice. Representative blot images correspond to the results of one 
experiment out of four. Data are expressed as mean ± SEM of 3-6 animals per group and analyzed by two-
way ANOVA followed by Tukey’s multiple comparison test. *p<0.05, **p<0.01, ***p<0.001 vs WT-vehicle; 
°p<0.05, °°p<0.01; °°°p<0.001 vs KO-vehicle. 
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Supplementary Methods
Score test
Mecp2 WT and KO mice were scored every other day to evaluate the effect of CBDV 
treatment on Hindlimb clasping, gait, breathing, tremor, mobility and general condition. Each 
of the six symptoms was scored from 0 to 2 (0 corresponds to the symptom being absent or 
the same as in the WT animal; 1 when the symptom was present; 2 when the symptom was 
severe). Specifically: For tremor: the mouse was observed while standing on the flat palm 
of the hand. 0 = no tremor; 1 =  intermittent mild tremor; 2 = continuous tremor or intermittent 
violent tremor. For hind limb clasping: 0 = WT; hind limbs splay outward when suspended 
by the tail; 1 = one hind limb is pulled into the body or forelimbs are stiff and splayed outward 
without motion; and 2 = one hind limb is pulled into the body and forelimbs are stiff and 
splayed outward without motion and might form a widened bowl shape or both hind limbs 
are pulled into the body with or without abnormal forelimb posture. For breathing: movement 
of flanks were observed while the animal was standing still. 0 = normal breathing; 1 = periods 
of regular breathing interspersed with short periods of more rapid breathing or with pauses 
in breathing; 2 = very irregular breathing-gasping or panting. For mobility: the mouse was 
observed when placed on bench, then when handled gently and scored as follows: 0 = as 
WT; 1 = reduced movement when compared with WT: extended freezing period when first 
placed on bench and longer periods spent immobile; 2 = no spontaneous movement when 
placed on the bench; mouse can move in response to a gentle prod or a food pellet placed 
nearby. For general condition: the mouse was observed for indicators of general well-being 
such as coat condition, eyes and body stance. 0 = clean shiny coat, clear eyes, and normal 
stance; 1 = eyes dull, coat dull/ungroomed, and somewhat hunched stance; 2 = eyes crusted 
or narrowed, piloerection, and hunched posture. For gait: 0 = as WT; 1 = hind limbs spread 
wider than WT when ambulating and/or a lower d pelvis when ambulating; and 2 = lack of 
full strides by hind limbs resulting in a dragging of hindquarters.
Table S1
DILUITION SUPPLIER
Rabbit polyclonal anti-BDNF 1:1000 Millipore, Italy
Goat polyclonal anti-IGF-1 1:1000 Millipore, Italy
Rabbit polyclonal anti-pAKT Ser473 1:1000 Cell Signaling, Danvers, MA
Rabbit polyclonal anti-phospho-rpS6 1:1000 Cell Signaling, Danvers, MA
Rabbit polyclonal anti-pERK1/2 1:1000 Cell Signaling, Danvers, MA
Rabbit polyclonal anti-cannabinoid CB1 receptor (CB1) 1:1000 Cayman Chemical,  Ann Arbor, MI
Rabbit polyclonal anti-cannabinoid CB2 receptor (CB2) 1:1000 Cayman Chemical,  Ann Arbor, MI
Rabbit polyclonal anti-N-acyl-phosphatidylethanolamine-
hydrolysing phospholipase D (NAPE-PLD) 1:3000
Cayman Chemical,  Ann Arbor, 
MI
Rabbit polyclonal anti-fatty acid amide hydrolase (FAAH) 1:2000 Cayman Chemical,  Ann Arbor, MI
Goat polyclonal anti-diacylglycerol Lipase α (DAGLα) 1:1000 Abcam, Cambridge, UK
Rabbit polyclonal anti-monoacylglycerol lipase (MAGL) 1:1000 Cayman Chemical,  Ann Arbor, MI
Table S1: List of primary antibodies used for Western blot analysis
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Supplementary figures
Figure S1
Figure S1: Timeline of the experiments
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Figure S2
Figure S2: Exploration times and locomotor activity in vehicle- and CBDV-treated Mecp2 WT and KO during 
the familiarization phase of the NOR test at PND 41 (A), 56 (B) and 66 (C). Left panels show the time spent 
exploring the two identical objects during the 10-minute session; right panels report total distance moved. 
Data are expressed as mean ± S.E.M. and analyzed using Student t test or two-way ANOVA.
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Figure S3
Short-term memory - PND 41
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Figure S3: Exploration times of the novel object and the familiar object in vehicle- and CBDV-treated Mecp2 
WT and KO during the test phase of the NOR test at PND 41 (A), 56 (B) and 66 (C). Data are expressed as 
mean ± S.E.M. and analyzed using Student t test. ***p<0.001, **p<0.01, *p<0.05 vs familiar object.
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Figure S4
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Figure S4: Protein levels of (A) BDNF and p-rpS6, (B) CB1 and CB2 receptors, (C) NAPE-PLD and FAAH, 
(D) DAGLα and MAGL in hemisected brains of pre-symptomatic 4-weeks-old Mecp2 WT and KO mice as 
measured by means of Western blot analysis.  Data are expressed as mean ± S.E.M. of 4 WT and 3 KO 
mice per group and were analyzed using unpaired Student t test. *p<0.05 vs WT.
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Figure S5
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Figure S5: Protein levels of cannabinoid CB1 and CB2 receptors and FAAH in hemisected brains of naïve 9-
weeks-old Mecp2 WT and KO mice (no handling) as measured by means of Western blot analysis.  Data are 
expressed as mean ± S.E.M. of 4 mice per group and analyzed using unpaired Student t test. *p<0.05 vs 
WT.
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